Panbela Provides Business Update and Reports Q2 2024 Financial Results
13 août 2024 16h10 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
30 juil. 2024 16h15 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
24 juin 2024 08h00 HE
|
Panbela Therapeutics, Inc.
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low...
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
10 juin 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Provides Business Update and Reports Q1 2024 Financial Results
15 mai 2024 16h10 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
06 mai 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
01 mai 2024 16h15 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
30 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
22 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Poster Presentation at American Association for Cancer Research:
18 avr. 2024 08h00 HE
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment...